Molecular Biology Reports

, Volume 40, Issue 3, pp 2697–2704 | Cite as

Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity

  • Vanessa A. Belo
  • Marcelo R. Luizon
  • Patrícia C. Carneiro
  • Valéria A. Gomes
  • Riccardo Lacchini
  • Carla M. M. Lanna
  • Debora C. Souza-Costa
  • Jose E. Tanus-Santos


Matrix metalloproteinase-2 is involved in the development of the adipose tissue, and associated with cardiovascular diseases. Metabolic risk factors (MRFs) and functional polymorphisms in the MMP-2 gene may affect its expression and activity. We investigated whether traditional MRFs and two MMP-2 gene polymorphisms (C−1306T; rs243865, and C−735T; rs2285053) affect circulating MMP-2 levels in children and adolescents, and whether MMP-2 polymorphisms and/or haplotype are associated with susceptibility to childhood obesity. We studied 114 healthy controls, 43 obese, and 83 obese with ≥3 MRFs children and adolescents. Genotypes were determined by Taqman allele discrimination assay and real-time PCR. Plasma MMP-2 was measured using zymography. We found positive correlations between MMP-2 concentrations and mean blood pressure in all children and adolescents group (r = 0.132; P < 0.05) and in obese children and adolescents (r = 0.247; P < 0.01). We found that the CC genotype for the C−1306T polymorphism was more common in subjects with higher MMP-2 concentrations in controls (P = 0.003) and in the obese group (P = 0.013). The CT genotype (OR = 0.40; P < 0.01) and the T allele (OR = 0.48; P < 0.01) for the C−735T polymorphism were less common in obese children and adolescents than in controls. The haplotypes distribution did not show significant differences between control and obese (P > 0.05). Ours findings show that blood pressure is associated with circulating MMP-2 concentrations, and that the CC genotype for the C−1306T polymorphism was more common subjects (controls and obese) with higher MMP-2 concentrations, whereas the CT genotype and the T allele for the C−735T polymorphism are less common in obesity.


Matrix metalloproteinase-2 Hypertension Childhood obesity Polymorphisms 


  1. 1.
    Wang G, Dietz WH (2002) Economic burden of obesity in youths aged 6 to 17 years: 1979–1999. Pediatrics 109(5):E81–E81PubMedCrossRefGoogle Scholar
  2. 2.
    Kotchen TA (2010) Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 23(11):1170–1178PubMedCrossRefGoogle Scholar
  3. 3.
    Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, Robinson TN, Scott BJ, St Jeor S, Williams CL (2005) Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 111(15):1999–2012PubMedCrossRefGoogle Scholar
  4. 4.
    Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444(7121):875–880PubMedCrossRefGoogle Scholar
  5. 5.
    Lijnen HR (2008) Angiogenesis and obesity. Cardiovasc Res 78(2):286–293PubMedCrossRefGoogle Scholar
  6. 6.
    Van Hul M, Lijnen HR (2008) A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 6(7):1198–1206PubMedCrossRefGoogle Scholar
  7. 7.
    Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D (2002) Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol 22(3):374–379PubMedCrossRefGoogle Scholar
  8. 8.
    Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573PubMedCrossRefGoogle Scholar
  9. 9.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE (2009) Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42(10–11):984–990PubMedCrossRefGoogle Scholar
  10. 10.
    Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412(19–20):1731–1739PubMedCrossRefGoogle Scholar
  11. 11.
    Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25(2):372PubMedCrossRefGoogle Scholar
  12. 12.
    Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198(2):320–331PubMedCrossRefGoogle Scholar
  13. 13.
    Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, Tanus-Santos JE, Gerlach RF (2010) Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 16(7):599–608PubMedCrossRefGoogle Scholar
  14. 14.
    Derosa G, Maffioli P, D’Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero AF (2009) Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 32(2):E124–E132PubMedGoogle Scholar
  15. 15.
    Miksztowicz V, Muzzio ML, Royer M, Prada M, Wikinski R, Schreier L, Berg G (2008) Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism 57(11):1493–1496PubMedCrossRefGoogle Scholar
  16. 16.
    Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, D’Angelo A (2007) Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium 14(4–5):175–183PubMedGoogle Scholar
  17. 17.
    Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Piccinni MN, Peros E, Geroldi D, Fogari E, D’Angelo A (2007) Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 14(1):45–51PubMedCrossRefGoogle Scholar
  18. 18.
    Derosa G, D’Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF (2010) Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res 79(2):144–149PubMedCrossRefGoogle Scholar
  19. 19.
    Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549–7558PubMedCrossRefGoogle Scholar
  20. 20.
    Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM, Oliveira SA, Vicente AM (2010) Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 11:40PubMedCrossRefGoogle Scholar
  21. 21.
    Singh R, Srivastava P, Srivastava A, Mittal RD (2010) Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 25(10):3393–3401PubMedCrossRefGoogle Scholar
  22. 22.
    Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64(20):7622–7628PubMedCrossRefGoogle Scholar
  23. 23.
    Han DH, Kim SK, Kang S, Choe BK, Kim KS, Chung JH (2008) Matrix metallopeptidase 2 gene polymorphism is associated with obesity in Korean population. Korean J Physiol Pharmacol 12(3):125–129PubMedCrossRefGoogle Scholar
  24. 24.
    Morgan AR, Han DY, Thompson JM, Mitchell EA, Ferguson LR (2011) Analysis of MMP2 promoter polymorphisms in childhood obesity. BMC Res Notes 4:253PubMedCrossRefGoogle Scholar
  25. 25.
    Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE (2012) Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 26(3):171–177PubMedCrossRefGoogle Scholar
  26. 26.
    Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G, Tanus-Santos JE (2012) Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 92(2):217–221PubMedCrossRefGoogle Scholar
  27. 27.
    Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC growth charts: United States. Adv Data 314:1–27PubMedGoogle Scholar
  28. 28.
    Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996). Pediatrics 98 (4 Pt 1):649–658Google Scholar
  29. 29.
    Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH (2003) Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 157(8):821–827PubMedCrossRefGoogle Scholar
  30. 30.
    Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350(23):2362–2374PubMedCrossRefGoogle Scholar
  31. 31.
    Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115(4):e500–e503PubMedCrossRefGoogle Scholar
  32. 32.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRefGoogle Scholar
  33. 33.
    Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE (2006) Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365(1–2):183–187PubMedCrossRefGoogle Scholar
  34. 34.
    Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40(1–2):119–123PubMedCrossRefGoogle Scholar
  35. 35.
    Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344(1):147–149PubMedCrossRefGoogle Scholar
  36. 36.
    Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38(5):410–414PubMedCrossRefGoogle Scholar
  37. 37.
    Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978–989PubMedCrossRefGoogle Scholar
  38. 38.
    Derosa G, Ferrari I, D’Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF (2008) Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4):219–224PubMedCrossRefGoogle Scholar
  39. 39.
    Glowinska-Olszewska B, Urban M, Florys B (2006) Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12(3):179–183PubMedGoogle Scholar
  40. 40.
    Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251–262PubMedGoogle Scholar
  41. 41.
    Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85(10):906–911PubMedCrossRefGoogle Scholar
  42. 42.
    Derosa G, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13(3):227–231PubMedCrossRefGoogle Scholar
  43. 43.
    Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K, Toutouza M, Stefanadis C, Toutouzas P (2004) The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 17(3):273–276PubMedCrossRefGoogle Scholar
  44. 44.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17):2089–2096PubMedCrossRefGoogle Scholar
  45. 45.
    Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE (2006) Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47(1):117–122PubMedCrossRefGoogle Scholar
  46. 46.
    Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C, Gerlach RF, Tanus-Santos JE (2011) Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 109(2):130–137PubMedCrossRefGoogle Scholar
  47. 47.
    Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, Tavella M, Schreier L, Berg GA (2009) Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 40(1):48–53PubMedCrossRefGoogle Scholar
  48. 48.
    Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, Ferraz KC, Tanus-Santos JE (2012) Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36(1):69–75CrossRefGoogle Scholar
  49. 49.
    Van Hul M, Piccard H, Lijnen HR (2010) Gelatinase B (MMP-9) deficiency does not affect murine adipose tissue development. Thromb Haemost 104(1):165–171PubMedCrossRefGoogle Scholar
  50. 50.
    Goncalves FM, Martins-Oliveira A, Lacchini R, Belo VA, Speciali JG, Dach F, Tanus-Santos JE (2013) Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. Gene 512(1):35–40PubMedCrossRefGoogle Scholar
  51. 51.
    Marson BP, Lacchini R, Belo V, Dickel S, da Costa BP, Poli de Figueiredo CE, Tanus-Santos JE (2012) Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease. Am J Nephrol 35(3):209–215PubMedCrossRefGoogle Scholar
  52. 52.
    Jacob-Ferreira AL, Lacchini R, Gerlach RF, Passos CJ, Barbosa F Jr, Tanus-Santos JE (2011) A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. Sci Total Environ 409(20):4242–4246PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Vanessa A. Belo
    • 1
  • Marcelo R. Luizon
    • 1
  • Patrícia C. Carneiro
    • 1
  • Valéria A. Gomes
    • 2
  • Riccardo Lacchini
    • 1
  • Carla M. M. Lanna
    • 3
  • Debora C. Souza-Costa
    • 4
  • Jose E. Tanus-Santos
    • 1
  1. 1.Department of Pharmacology, Faculty of Medicine of Ribeirao PretoUniversity of Sao PauloRibeirao PretoBrazil
  2. 2.Department of Pharmacology, Faculty of Medical SciencesState University of CampinasCampinasBrazil
  3. 3.Department of PhysiologyFederal University of Juiz de ForaJuiz de ForaBrazil
  4. 4.Department of BiologyFederal University of Juiz de ForaJuiz de ForaBrazil

Personalised recommendations